Best Compounded Tirzepatide in Salem, OR 2026 (Ranked Providers)

Key Takeaways

• Tirzepatide 15 mg produced a mean body weight reduction of approximately 22.5% at 72 weeks in adults with obesity without diabetes; the 5 mg and 10 mg doses produced 16.0% and 21.4% reductions respectively. (Source: SURMOUNT-1, NEJM 2022)
• In a 40-week head-to-head trial of patients with type 2 diabetes, tirzepatide 15 mg produced approximately 11.2 kg of body-weight reduction vs 5.7 kg on semaglutide 1 mg. (Source: SURPASS-2, NEJM 2021)
• Tirzepatide reduced the apnea-hypopnea index by approximately 27 to 30 events/hour at 52 weeks in adults with obesity and moderate-to-severe obstructive sleep apnea, vs roughly 5 events/hour reduction on placebo. (Source: SURMOUNT-OSA, NEJM 2024)
• Tirzepatide is the active pharmaceutical ingredient; it is FDA-approved in the corresponding brand finished products (Zepbound and Mounjaro). Trimi's compounded preparation of the same active ingredient is prepared per individual prescription by 503A community sterile compounding pharmacies and is not itself FDA-approved as a drug.
• Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
• Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
• This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.